S

Sosei Group Corp
TSE:4565

Watchlist Manager
Sosei Group Corp
TSE:4565
Watchlist
Price: 1 033 JPY 1.08% Market Closed
Market Cap: 92.9B JPY
Have any thoughts about
Sosei Group Corp?
Write Note

Sosei Group Corp
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Sosei Group Corp
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
S
Sosei Group Corp
TSE:4565
Cash & Cash Equivalents
ÂĄ48.9B
CAGR 3-Years
-1%
CAGR 5-Years
19%
CAGR 10-Years
20%
Takeda Pharmaceutical Co Ltd
TSE:4502
Cash & Cash Equivalents
ÂĄ859B
CAGR 3-Years
12%
CAGR 5-Years
10%
CAGR 10-Years
2%
Daiichi Sankyo Co Ltd
TSE:4568
Cash & Cash Equivalents
ÂĄ707.7B
CAGR 3-Years
9%
CAGR 5-Years
19%
CAGR 10-Years
15%
Otsuka Holdings Co Ltd
TSE:4578
Cash & Cash Equivalents
ÂĄ515.1B
CAGR 3-Years
5%
CAGR 5-Years
6%
CAGR 10-Years
1%
Chugai Pharmaceutical Co Ltd
TSE:4519
Cash & Cash Equivalents
ÂĄ462.9B
CAGR 3-Years
34%
CAGR 5-Years
21%
CAGR 10-Years
16%
Astellas Pharma Inc
TSE:4503
Cash & Cash Equivalents
ÂĄ293B
CAGR 3-Years
-3%
CAGR 5-Years
-1%
CAGR 10-Years
-4%
No Stocks Found

Sosei Group Corp
Glance View

Market Cap
92.9B JPY
Industry
Pharmaceuticals

Sosei Group Corp. engages in the discovery, design, and development of medicines targeting G protein-coupled receptors (GPCRs). The company is headquartered in Chiyoda-Ku, Tokyo-To and currently employs 198 full-time employees. The company went IPO on 2004-07-29. The pharmaceutical business is engaged in the research, development and sales of medicines, the management of regenerative medical funds, the investment in bio venture companies related to regenerative medicine, the overseas development by licensing, the promotion of commercialization, the structural analysis of GPCR, the initial lead compound creation, the candidate search by proprietary StaR technology, as well as structural base of new drugs using GPCR related basic technology drug discovery, screening, promotion of antibody drug research and development.

Intrinsic Value
1 330.98 JPY
Undervaluation 22%
Intrinsic Value
Price
S

See Also

What is Sosei Group Corp's Cash & Cash Equivalents?
Cash & Cash Equivalents
48.9B JPY

Based on the financial report for Sep 30, 2024, Sosei Group Corp's Cash & Cash Equivalents amounts to 48.9B JPY.

What is Sosei Group Corp's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
20%

Over the last year, the Cash & Cash Equivalents growth was 15%. The average annual Cash & Cash Equivalents growth rates for Sosei Group Corp have been -1% over the past three years , 19% over the past five years , and 20% over the past ten years .

Back to Top